Clinical Trial Detail

NCT ID NCT02680951
Title Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Emory University
Indications

acute myeloid leukemia

Therapies

Cytarabine + Dasatinib + Fludarabine + Idarubicin

Age Groups:

No variant requirements are available.